Nextera™ Flex for Enrichment is the fastest and most flexible targeted sequencing solution for DNA in the Illumina library prep portfolio:
Nextera Flex for Enrichment uses a fast, user-friendly workflow. On-bead tagmentation chemistry is combined with a simplified, single hybridization protocol to reduce total workflow time. From DNA input and extraction to library normalization, enrichment, and post-enrichment amplification, the total assay time is ~ 6.5 hours, and total hands-on time is ~2 hours.
Nextera Flex for Enrichment supports a broad DNA input range (10-1000 ng high-quality genomic DNA or 50 ng FFPE DNA) and multiple sample types, including blood, saliva, genomic DNA, and formalin-fixed, paraffin-embedded (FFPE) tissue. The Flex Lysis Reagent Kit enables fast DNA extraction from blood and saliva samples to go directly into library prep, reducing the number of required quantification steps to maximize cost-effectiveness.
While accommodating various study requirements, the Nextera Flex for Enrichment solution delivers consistent insert sizes, uniform coverage, optimized performance, and highly reproducible data across all Illumina sequencing systems.
Library preparation for Illumina sequencing consists of DNA fragmentation and adapter-tagging. DNA fragmentation can be achieved using enzymatic or mechanical methods. Enzymatic methods are typically more convenient but can create challenges around sensitivity to DNA quantitation, and/or require extensive optimization to achieve robustness.
Nextera Flex is a novel bead-linked-transposome technology, which addresses these shortcomings whilst retaining the convenience of enzymatic fragmentation. Nextera Flex is compatible with a wide range of DNA inputs, providing new levels of robustness while minimizing the requirement for quantitation post-library prep for an input range of 100-500ng for whole genome sequencing and 50-1000ng for targeted enrichment. In addition, the underlying technology will normalize the libraries to give a consistent yield and insert size from a range of DNA inputs. When paired with the Nextera Flex lysis kit, customers can employ a quantification-free workflow to enable normalized library creation from raw samples such as blood and saliva. This new technology offers customers a novel, easy-to-use, fast, and simple solution for library preparation.
Microbiome research is quickly becoming one of the most exciting fields in the life sciences, driven by the power of next-generation sequencing (NGS). One Codex is a leading platform for rapid, accurate microbiome and metagenomics analysis and is used by researchers across major academic, commercial, and clinical institutions. In this webinar, we will walk through a gut microbiome experiment including sample collection, sequencing, bioinformatics, and analysis.
On the bioinformatics side, we will show how you can easily analyze NGS datasets with the One Codex database of >80,000 whole microbial genomes. We will review several types of microbiome analyses from taxonomic classification to building predictive machine learning models. Finally, we will demonstrate how it can all be performed in a scalable, repeatable fashion, ensuring that your microbiome research is reproducible whether it involves 10 samples or 10,000.
Understanding the microbial ecosystem dynamics of our planet is central to our role as custodians of the planet. The Earth Microbiome Project aimed to characterize the microbial diversity of the diverse ecosystems across our world, which we have used to model the ecosystem dynamics of these environments. Integrating these models with agricultural policy provides a framework on which to determine how climate change and shifting policy will influence the microbial metabolic dynamics, which will affect our ability to modulate system scale outcomes. In concert with this global perspective we are also characterizing the human microbiome, which has become a key part of patient care, provide new avenues to diagnose and treat human disease. The immune system controls our interaction with the microbial world, and yet the microbial communities in our bodies are central to modulating the immune response. Changes in the human microbiome have substantial influence on atopy, neurological disorders, metabolic disorders, and a range of complex conditions and disease states. We will discuss evidence of these mechanisms of interaction and how we have started to disturb the delicate balance of the immune-microbe equilibrium, impacting the development and function of our immune systems. Central to this disturbance is the distance we have placed between our children and the microbial world, which has been demonstrated to have a substantial influence on their physiological, immunological, neurological and even endocrinological development. Applying new strategies to identify how the microbial ecosystem correlates with diseases states and treatment efficacy through Microbiome-Wide Association Studies (MWAS) is altering the trajectory of precision medicine, and providing a new framework for facilitating patient care.
Jack Gilbert is the Faculty Director of the Microbiome Center, a Professor in the Department of Surgery at the University of Chicago Medicine, Senior Scientist (Adjunct) at Marine Biological Laboratory, and Group Leader in Microbial Ecology at Argonne National Laboratory. Gilbert's research is focused on the ecology, evolution, and metabolic dynamics of microbial ecosystems from myriad environments including built environments, oceans, rivers, soils, air, plants, animals, and humans. His primary interest is in using omics technologies (metagenomics, metatranscriptomics, metabolomics) to capture longitudinal dynamics in microbial ecosystems and then model how these interactions relate the environmental variables, be those variables disease onset and immunology in humans or chemical transformations in plants and soils. Gilbert is developing unifying principles which govern how microbial communities assemble. He founded the Earth Microbiome Project, and co-founded the American Gut Project, and is the editor-in-chief of the journal mSystems.
Genomics is facilitating a deeper understanding of cancer biology and through clinical research, new biomarkers are emerging that pave the way for next-generation therapeutics to help fight cancer in a more personalized way.
In this webinar, Sandip Patel, MD will provide a review of biomarker research and discoveries in the field of Immunotherapy and Garret Hampton, PhD will discuss Illumina’s vision for Oncology and share how genomics will enable broader availability of comprehensive tumor sequencing to explore complex biomarkers and assess tumor mutational burden.
Explore our smallest and most cost-effective sequencer ever. Join Bellal Moghis and Gary Schroth as they introduce our newest system—iSeq 100. They’ll walk through installation and also review applications and methods. Find out how you can make the most of your new lab partner.
With the dramatically increasing amount of sequence data generation and the significant reduction of sequencing costs, rapid, easy, and accurate data analytics becomes the critical bottleneck in adopting next-generation sequencing (NGS) in the public health sector. To this end, CosmosID has developed a cloud-based microbial genomics platform featuring with world’s largest curated genome databases and scaling computational power to keep pace with the ever-increasing amount of data generation. The platform brings together the most comprehensive and ultrafast “sequence to answer” workflow for easy, accurate, and highly resolved profiling of cross-disciplinary microbiome data. In this webinar, various aspects of the platform will be presented with reference to recent studies on water and wastewater treatment, food safety, molecular epidemiology, and multi-kingdom microbiome profiling and characterization. Key technologies that will be showcased include strain-level metagenomics, metatranscriptomics, metagenomic assembly, and molecular sub-typing.
See what happens when a leading library prep is optimized to run on next-generation sequencing (NGS) systems from Illumina. Join Mitu Chaudhary and Claire White as they present data to demonstrate the robust performance of AmpliSeq for Illumina from a wide variety of sample types.
The latest sequencing technologies enable unprecedented throughput and redefine limits for many labs. To adapt, these labs must redefine how they work – by automating tasks to reduce touchpoints and by simplifying workflows with integration and robust analysis tools. In this webinar, we describe BaseSpace™ Sequence Hub and how the newest features support high throughput, high-volume sequencing. We demonstrate how customers can progress from flowcell loading to variant analysis with zero touchpoints by using the Whole Genome Sequencing or Edico Genome DRAGEN apps. Additionally, we describe how the integration with BaseSpace™ Variant Interpreter enables users to interpret and generate reports of identified variants.
Pharmacogenetic (PGx) testing enables researchers to understand a
person’s genetic propensity for a therapeutic response or an adverse
reaction to particular medications. Recently the NIH’s Precision
Medicine Initiative has begun a nationwide effort to individualize a
subject’s treatment program, while the FDA has already included PGx
information in over one hundred drug labels. Serious drug reaction
events are likely to become more prevalent as more drugs become
available and the number of pharmaceuticals each person is taking
increases. To understand the occurrence of these events, sequencing
genomic regions associated with metabolism of a wide-spectrum of drug
classes can help inform clinical researchers, and better characterize
the frequency of known and novel haplotypes within validated genes
involved in drug metabolism pathways.
In this presentation, we will describe a method and workflow for targeted pharmacogenetic gene sequencing using Kailos’ TargetRichTM PGxComplete assay.
The Webinar Series will feature HLA laboratory directors presenting
case studies from samples prepared with TruSight™ HLA, sequenced with
Illumina next-generation sequencing (NGS) MiSeq or MiniSeq systems,
and analyzed using TruSight HLA Assign software. Presentations will be
followed by an interactive question and answer session.
The webinar will offer participants:
The latest NovaSeq advancements have arrived—delivering unprecedented scalability and flexibility for next-generation sequencing (NGS). Discover how the S4 flow cell allows you to use the NovaSeq 6000 System to take your research to the next level.
Join Gary Schroth, Illumina Distinguished Scientist, to learn about these latest advancements with the NovaSeq 6000 System. See how the S4 can provide you the highest throughput of any sequencer. Finally, with the new NovaSeq Xp workflow, you can expand your research, giving you more flexibility than ever before.
Professor Torsten Haferlach, Head of Munich Leukemia Laboratory (MLL), will present their experience with large-scale sequencing including the use of artificial intelligence strategies to perform whole genome sequencing (WGS) and RNA sequencing on 5000 samples.
The Webinar Series will feature HLA laboratory directors presenting case studies from samples prepared with TruSight™ HLA, sequenced with Illumina next-generation sequencing (NGS) MiSeq or MiniSeq systems, and analyzed using TruSight HLA Assign software. Presentations will be followed by an interactive question and answer session.
The webinar will offer participants:
Dr Dolly Tyan will present on the Stanford Immunogenetics labs’ experience validating TruSight® HLA v2 for NGS HLA typing and validation of automation for TruSight HLA library prep. Dr Tyan will also share a case study to illustrate the utility of NGS HLA typing test results in solid organ transplantation research.
This presentation is part of the TruSight HLA Webinars Series which features HLA lab directors presenting case studies from samples prepared with TruSight HLA, sequenced with Illumina next-generation sequencing (NGS) MiSeq® or MiniSeq® systems, and analyzed using TruSight HLA Assign™ software.
Medical societies now recommend that all women, regardless of age, be offered screening and diagnostic testing for aneuploidy during pregnancy.1-2 Noninvasive prenatal testing (NIPT) is a newer screening option that utilizes the presence of cell-free DNA in a pregnant woman’s blood originating from the pregnancy. Whole-genome sequencing-based NIPT can screen for common aneuploidies (trisomy 21, trisomy 18, trisomy 13, and certain sex chromosome aneuploidies) with greater accuracy than other available screening modalities, resulting in a significant reduction in false positive rates and, subsequently, potential reduction in invasive procedures in healthy pregnancies.3
In this webinar, Tina Ziainia, MD, FACOG, an Obstetrician-Gynecologist affiliated with Sharp HealthCare, provides insight and expertise on successfully implementing NIPT into a busy practice. Having been in practice for over 17 years and having offered NIPT since 2013, she’ll also discuss prenatal screening options, review the latest ACOG and ACMG screening guidelines, and identify helpful resources for both you and your patients.
1. Practice Bulletin No. 163: Screening for Fetal Aneuploidy. Obstet Gynecol. 2016;127(5):979-981.
2. Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal
screening for fetal aneuploidy, 2016 update: a position statement of
the American College of Medical Genetics and Genomics. Genet
Med. 2016: doi:10.1038/gim.2016.97.
3. Bianchi DW, Rava RP, Sehnert AJ. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;371(6):578.
The Webinar Series will feature HLA laboratory directors presenting case studies from samples prepared with TruSight HLA, sequenced with Illumina next-generation sequencing (NGS) MiSeq or MiniSeqvsystems, and analyzed using TruSight HLA Assign software. Presentations will be followed by an interactive question and answer session.
The webinar will offer participants:
To gain efficiency in the lab, multigene testing is rapidly being adopted for tumor profiling. TruSight Tumor 15 (TST15) is a next-generation sequencing (NGS)-based assay which includes the 15 most common cancer biomarkers, and delivers a streamlined solution for multigene testing.
Join the webinar to find out about:
Brugada Syndrome belongs to a family of rare inherited cardiac disorders that can lead to sudden cardiac death. Rare genetic variants in the SCN5A gene can be identified in ~20%* of cases with Brugada Syndrome, while the genetic basis in the others remains unresolved.
Ongoing studies, combining data from multiple genomic methods, are helping to elucidate the genetic basis of Brugada Syndrome and other complex cardiac disorders with the aim of improving patient care in the future.
Register for the webinar to hear Professor Connie Bezzina present data from her laboratory and ongoing collaborative studies with the Brugada Syndrome Genetics Consortium.
This webinar will provide an overview of the development, validation and clinical evaluation of PathoQuest’s iDTECT Blood. This CE IVD test represents an application of NGS-based shotgun metagenomics to the field of infectious disease diagnosis. The test provides microbiologists and clinicians a precision diagnostics tool allowing individualized antimicrobial treatment decisions in patients where current microbiological methods frequently fail to identify a responsible pathogen. Both the sample preparation and the bioinformatic pipeline have been optimized to provide high sensitivity and accuracy and an actionable report. Clinical results from a prospective study recently published in Clinical Microbiology and Infection will also be discussed.
The Webinar Series will feature HLA laboratory directors presenting case studies from samples prepared with TruSight HLA, sequenced with Illumina next-generation sequencing (NGS) MiSeq or MiniSeq systems, and analyzed using TruSight HLA Assign software. Presentations will be followed by an interactive question and answer session.
The webinar will offer participants:
Mechanisms of microbial pathogenicity have been extensively analyzed using a broad spectrum of methods, which are driven largely by the technologies available at that time. As animal experimentation gave way to in vitro methods, specific pathogens were systematically investigated as individual dominant clones and colonizers. With the arrival of next-generation sequencing, microbiomes of very diverse habitats are being described. Thus, the microbiome of newborns versus those of the elderly are now prescribed, also the transition and shift in complexity and specificity of bacteria from the oral cavity through to the gut compared to the skin and respiratory are now cataloged and mapped across communities and in response to stress and stimuli. This tremendous leap in deciphering the human microbiome has ushered a new era of microbiology in which formidable challenges in establishing the foundation of taxonomy, dynamics and function of the residential microbial communities dominate.
This talk will present the progress made in metagenomics and the use of largely unassembled sequences in constructing the microbial communities forming the human microbiome. The knowledge assembled from microbial whole genome sequences, and the metabolic traits of the human flora are perhaps the most significant framework for the construction of reference microbiomes that can drive research into how transient pathogens establish in new niches and drive the shift from health to disease.
The Webinar Series will feature HLA laboratory directors presenting case studies from samples prepared with TruSight™ HLA, sequenced with Illumina next-generation sequencing (NGS) MiSeq® or MiniSeq™ systems, and analyzed using TruSight™ HLA Assign software. Presentations will be followed by an interactive question and answer session.
The webinar will offer participants:
• Advanced sequencing data analysis and data interpretation in Assign software
• Continuing education in current and relevant topics in Histocompatibility and Immunogenetics
• An opportunity to share best practices and troubleshooting tips in data analysis and HLA typing by NGS
• A forum for interaction with other NGS users
This is an official continuing education program approved by the American Board of Histocompatibility and Immunogenetics (ABHI). Attendees are eligible to receive 0.225 ABHI continuing education credits (CEC).
There is no charge for this event but registration is
For Research Use Only. Not for use in diagnostic procedures.
The Webinar Series will feature HLA laboratory directors presenting case studies from samples prepared with TruSight HLA , sequenced with Illumina next-generation sequencing (NGS) MiSeq or MiniSeq systems, and analyzed using TruSight HLA Assign software.
Discover a new era of sequencing with the NovaSeq Series. Join us for a live webinar event to see firsthand how we are redefining what is possible with high-throughput sequencing. Built from the ground up to fulfill your scientific visions, the NovaSeq Series gives you the flexibility and scalability to complete projects faster and more economically than ever before across a broad range of applications.
Webinar at a glance
Abstract: High throughput sequencing, combined with a high resolution bioinformatics platform, provides a powerful tool for researching enteric diseases and for agricultural and environmental applications. Results of a case control study, comprising samples of known and unknown disease etiology, as well as healthy individuals showed the intestinal microbiome could potentially be used in differentiating healthy, diseased, and asymptomatic carriers, as well as individuals in early stages of infection. Other examples include microbiology of wastewater reuse demonstrating the power of metagenomics to identify the microbial community of pathogens, indicator organisms, and natural microbiota to determine the safety of drinking water derived from recycled wastewater. The CosmosID system provides identification to species and strain within minutes, offers information on antibiotic resistance and pathogenicity factors, and provides relative abundance. The system has been used in analyzing over 25,000 samples to date.
For Research Use Only. Not for use in diagnostic procedures.
As researchers seek to understand how the transcriptome shapes
biology, RNA-Seq is
becoming recognized as one of the most significant and powerful tools in modern science. With RNA-Seq, researchers can detect the fine architecture of the transcriptome, such as transcript isoforms, gene fusions, single nucleotide variants, and other features—without prior knowledge. In addition to RNA-Seq, methylation sequencing can provide insights into the regulation of RNA and the temporal and spatial expression of gene products. By combining both RNA and methylation sequencing, researchers who study complex disease, cancer, and other biological systems will have a more complete picture of the transcriptome and its underlying regulatory features.
In this live webinar, we discuss the RNA-Seq and Methyl-Seq workflows that can help researchers drive breakthroughs and understanding in the area of gene expression and gene regulation. Join our gene expression and methylation experts as they review how researchers are driving discovery and learn how our workflows can help your lab leverage the power of next-generation sequencing.
Dr. Petrosino is exploring the comprehensive taxonomic and functional changes in the microbiome between birth and Type-1 Diabetes onset in over 22,000 samples from 820 cases and controls (1:1 match) in the TEDDY (The Environmental Determinants of Diabetes in the Young) international prospective cohort.
Advanced analyses of 16S rRNA gene, and bacterial/viral metagenomic data will be presented in this webinar.
Next Generation Sequencing (NGS) methods are arguably responsible for the establishment of the field of metagenomics. Significantly lower nucleic acid input requirements have made it possible to sample microbial communities that would have been deemed undetectable just a few years ago. In addition to technological advancements, the continued decline in the cost of sequencing has made it feasible to survey the thousands of samples necessary for metagenomic analyses. To meet the throughput demands of these studies, we have automated NGS sample processing methods from nucleic acid extraction, through library normalization, and pooling.
Here, we will present automated methods for 16S rDNA amplicon and whole genome shotgun sequencing as well as discuss the impact of automation on quality. The resulting sequencing reads from both approaches were compared for quality metrics using our standard quality matrix (Q30, Cluster Density, number of mapped reads, etc.)
Subsequently, sequencing reads were used for taxonomic identification and a comparative analysis. Although both automated methods offer a significant benefit in throughput, we found the reduction in the risk of human error far outweighs all other benefits. Furthermore, utilization of automated liquid handling reduces the risk of contamination.
The excitement surrounding immuno-oncology is being driven by results seen in the clinic. New treatments can potentially be made more efficacious using NGS technology that would accelerate biomarker identification and bring down costs for research subject screening and safety monitoring. Among these technologies is RNA-Seq, a flexible sequencing assay that enables multiple applications with one assay from a single sample. In this webinar, we'll summarize the clinical relevance of RNA-Seq, when and how to use expression profiling economically, some common challenges and associated remedies.
|Key learning objectives|